Autor segons l'article: Cano A, Ettcheto M, Espina M, Auladell C, Calpena AC, Folch J, Barenys M, Sánchez-López E, Camins A, García ML.
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Folch Lopez, Jaume
Paraules clau: Polymeric nanoparticles; Plga-peg; Neurodegeneration; Epilepsy; Epigallocatechin-3-gallate; plga-peg; epilepsy; epigallocatechin-3-gallate
Resum: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. Epigallocatechin-3-gallate has aroused much interest because of its multiple therapeutic effects, but its instability compromises the potential effectiveness. PEGylated-PLGA nanoparticles of Epigallocatechin-3-gallate were designed to protect the drug and to increase the brain delivery. Nanoparticles were prepared by the double emulsion method and cytotoxicity, behavioral, Fluoro-Jade C, Iba1 and GFAP immunohistochemistry studies were carried out to determine their effectiveness. Nanoparticles showed an average size of 169 nm, monodisperse population, negative surface charge, encapsulation efficiency of 95% and sustained release profile. Cytotoxicity assays exhibited that these nanocarriers were non-toxic. Behavioral test showed that nanoparticles reduced most than free drug the number of epileptic episodes and their intensity. Neurotoxicity and immunohistochemistry studies confirmed a decrease in neuronal death and neuroinflammation. In conclusion, Epigallocatechin-3-gallate PEGylated-PLGA nanoparticles could be a suitable strategy for the treatment of temporal lobe epilepsy.
Àrees temàtiques: Química; Psicología; Pharmaceutical science; Odontología; Nanoscience and nanotechnology; Nanoscience & nanotechnology; Molecular medicine; Medicine, research & experimental; Medicine (miscellaneous); Medicina veterinaria; Medicina iii; Medicina ii; Medicina i; Materials science (miscellaneous); Materials science (all); Materiais; Interdisciplinar; General medicine; General materials science; Farmacia; Engenharias iv; Engenharias iii; Engenharias ii; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Ciências agrárias i; Biotecnología; Biomedical engineering; Bioengineering; Astronomia / física
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 15499634
Adreça de correu electrònic de l'autor: jaume.folch@urv.cat
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/abs/pii/S1549963418300315?via%3Dihub
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Nanomedicine-Nanotechnology Biology And Medicine. 14 (4): 1073-1085
Referència de l'ítem segons les normes APA: Cano A, Ettcheto M, Espina M, Auladell C, Calpena AC, Folch J, Barenys M, Sánchez-López E, Camins A, García ML. (2018). Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy.. Nanomedicine-Nanotechnology Biology And Medicine, 14(4), 1073-1085. DOI: 10.1016/j.nano.2018.01.019
DOI de l'article: 10.1016/j.nano.2018.01.019
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2018
Tipus de publicació: Journal Publications
Repositori URV